Osimertinib: tested in a combination
54 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingNCT07486648Phase 1/2Report a problem
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingNCT07485452Phase 2Report a problem
- Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyRecruitingNCT07398599Not applicableReport a problem
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingNCT07323641Phase 2Report a problem
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 4Report a problem
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingNCT07153055Phase 1/2Report a problem
- A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingNCT07058519Phase 2Report a problem
- Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT06918782Phase 2Report a problem
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Not applicableReport a problem
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingNCT06486142Phase 3Report a problem
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1Report a problem
- Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatRecruitingNCT05748093Phase 4Report a problem
- Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeRecruitingNCT04335292Phase 2Report a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2Report a problem
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results postedReport a problem
- Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results postedReport a problem
- A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results postedReport a problem
- A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results postedReport a problem
- Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesCompletedNCT03463525Phase 1Results postedReport a problem
- Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT02954523Phase 1/2Results postedReport a problem
- Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersCompletedNCT02803203Phase 1/2Results postedReport a problem
- A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompletedNCT02789345Phase 1Results postedReport a problem
- AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Active, not recruitingNCT02511106Phase 3Results postedReport a problem
- Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompletedNCT02454933Phase 3Results postedReport a problem
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results postedReport a problem
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02296125Phase 3Results postedReport a problem
- Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results postedReport a problem
- Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results postedReport a problem
- Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.Status unknownNCT06018688Phase 2Report a problem
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2Report a problem
- A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLCActive, not recruitingNCT05773092Phase 2Report a problem
- Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2Report a problem
- Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2Report a problem
- A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnNCT05120960Phase 1Report a problem
- Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerStatus unknownNCT05104281Phase 3Report a problem
- Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2Report a problem
- Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2Report a problem
- Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseCompletedNCT04541407Phase 1Report a problem
- Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2Report a problem
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2Report a problem
- Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1Report a problem
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2Report a problem
- Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerTerminatedNCT03891615Phase 1Report a problem
- Pharmacokinetic Boosting of OsimertinibCompletedNCT03858491Early Phase 1Report a problem
- Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3Report a problem
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedNCT03810807Phase 1Report a problem
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2Report a problem
- A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersActive, not recruitingNCT03567642Phase 1Report a problem
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2Report a problem
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2Report a problem
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2Report a problem
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedNCT02228369Phase 1Report a problem
- AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive, not recruitingNCT02143466Phase 1Report a problem